The retaliatory measures followed Trump's controversial move to order the withdrawal of all U.S. troops from Syria's northern border with Turkey.Politicsread more
Bloomberg could be in for a showdown with Elizabeth Warren, whether he runs or not.2020 Electionsread more
As the season kicks into gear this week, S&P 500 firms are expected to report a 4.6% earnings decline over the same period a year agoEarningsread more
"I think that may have scared the Chinese that they were going to get into a serious trade war with access to our capital markets being cut off, among other things," Michael...China Politicsread more
David Rolfe, a longtime Berkshire Hathaway shareholder and CIO at Wedgewood Partners, is fed up with Warren Buffett.Marketsread more
Bank of America says investors should still look to stocks for value rather than bonds.Investingread more
Wall Street analysts estimate GM has lost more than $1 billion due to the United Auto Workers' strike, which began Sept. 16.Autosread more
Top financial companies will mark the unofficial start of earnings season with their reports this week, and experts are offering several recommendations for trading the moves.ETF Edgeread more
The indexes traded in a tight range as investors looked ahead to the start of the earnings season while grappling with new worries over trade.Marketsread more
The union that represents Southwest Airlines pilots don't expect the grounded Boeing 737 Max to return until at least February, about a month later than the airline expects.Airlinesread more
Check out the companies making headlines in midday trading:Market Insiderread more
* Now sees EPS growth of 5%, vs earlier 3-5% target
* Surge in sales of Dupixent (Adds context)
PARIS, July 29 (Reuters) - Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses.
The French drugmaker said on Monday it was now eyeing earnings per share growth of around 5% compared to an earlier target range of 3-5%.
The group is betting on the strong uptake of its drug Dupixent, initially prescribed for atopic dermatitis and later approved for asthma and chronic rhinosinusitis, as it continues marketing and launches of the product.
Sales of Dupixent, developed with U.S firm Regeneron rose 168% in the second quarter to 496 million euros ($551.80 million).
Second quarter business net income rose 4.9% at constant exchange rates to 1.64 billion euros while sales were up 3.9% to 8.63 billion euros.
Sanofi booked an 1.8 billion euros impairment charge of intangible assets in the quarter related to hemophilia product Eloctate, after lower sales in the U.S. and a revision of sales projections.
Eloctate's revenue fell 11%, a result of direct competition from Roche's Hemlibra, a newcomer in the market.
Eloctate was developed by U.S. hemophilia specialist Bioverativ which Sanofi agreed to buy last year for $11.6 billion.
($1 = 0.8988 euros) (Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)